Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.34
HZNP's Cash to Debt is ranked lower than
79% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. HZNP: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: N/A
Current: 0.34
Equity to Asset 0.40
HZNP's Equity to Asset is ranked lower than
79% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HZNP: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.45 Max: 0.7
Current: 0.4
-0.77
0.7
Interest Coverage 0.30
HZNP's Interest Coverage is ranked lower than
98% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. HZNP: 0.30 )
Ranked among companies with meaningful Interest Coverage only.
HZNP' s Interest Coverage Range Over the Past 10 Years
Min: 0.79  Med: 0.79 Max: 0.79
Current: 0.3
F-Score: 5
Z-Score: 0.89
M-Score: -1.37
WACC vs ROIC
9.54%
-5.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.76
HZNP's Operating margin (%) is ranked lower than
66% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. HZNP: 2.76 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s Operating margin (%) Range Over the Past 10 Years
Min: -1841.5  Med: -229.83 Max: 7.31
Current: 2.76
-1841.5
7.31
Net-margin (%) 1.61
HZNP's Net-margin (%) is ranked lower than
68% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. HZNP: 1.61 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s Net-margin (%) Range Over the Past 10 Years
Min: -1635.12  Med: -324.26 Max: 5.22
Current: 1.61
-1635.12
5.22
ROE (%) 1.18
HZNP's ROE (%) is ranked lower than
67% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. HZNP: 1.18 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s ROE (%) Range Over the Past 10 Years
Min: -523.78  Med: -111.48 Max: 4.27
Current: 1.18
-523.78
4.27
ROA (%) 0.50
HZNP's ROA (%) is ranked lower than
66% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. HZNP: 0.50 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s ROA (%) Range Over the Past 10 Years
Min: -186.55  Med: -63.12 Max: 1.89
Current: 0.5
-186.55
1.89
ROC (Joel Greenblatt) (%) 88.89
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. HZNP: 88.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7948.82  Med: -1996.11 Max: 520.88
Current: 88.89
-7948.82
520.88
Revenue Growth (3Y)(%) 112.60
HZNP's Revenue Growth (3Y)(%) is ranked higher than
98% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. HZNP: 112.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.50 Max: 112.6
Current: 112.6
0
112.6
» HZNP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

HZNP Guru Trades in Q2 2015

RS Investment Management 964,160 sh (New)
Steve Mandel 3,204,972 sh (New)
Jim Simons 1,216,800 sh (+238.54%)
Paul Tudor Jones 137,400 sh (+201.92%)
Steven Cohen 325,000 sh (+38.95%)
» More
Q3 2015

HZNP Guru Trades in Q3 2015

Ron Baron 31,999 sh (New)
Steve Mandel 15,600,988 sh (+386.77%)
RS Investment Management 1,383,550 sh (+43.50%)
Jim Simons 465,912 sh (-61.71%)
Paul Tudor Jones 12,038 sh (-91.24%)
Steven Cohen 900 sh (-99.72%)
» More
Q4 2015

HZNP Guru Trades in Q4 2015

Ken Heebner 205,000 sh (New)
Julian Robertson 823,577 sh (New)
Joel Greenblatt 2,075,017 sh (New)
Paul Tudor Jones 48,570 sh (+303.47%)
RS Investment Management 2,210,448 sh (+59.77%)
Steve Mandel 15,600,988 sh (unchged)
Ron Baron Sold Out
Steven Cohen Sold Out
Jim Simons 302,400 sh (-35.10%)
» More
Q1 2016

HZNP Guru Trades in Q1 2016

Steven Cohen 1,019,400 sh (New)
Ken Heebner 330,000 sh (+60.98%)
Paul Tudor Jones 72,983 sh (+50.26%)
Julian Robertson 868,477 sh (+5.45%)
Jim Simons Sold Out
Steve Mandel 13,997,232 sh (-10.28%)
RS Investment Management 1,453,024 sh (-34.27%)
Joel Greenblatt 1,053,933 sh (-49.21%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:CTLT, OTCPK:STDAF, OTCPK:INVVY, OTCPK:GEDSF, OTCPK:CHSYF, NAS:MDCO, NYSE:DPLO, OTCPK:SWPIF, OTCPK:SHPHF, NAS:IPXL, NAS:AKRX, NAS:ENDP, NAS:IRWD, NAS:RDUS, NAS:NBIX, NAS:INNL, NAS:PCRX, NAS:CPXX, OTCPK:HTSUF, NAS:DEPO » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.

Ratios

vs
industry
vs
history
P/E(ttm) 212.24
HZNP's P/E(ttm) is ranked lower than
94% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. HZNP: 212.24 )
Ranked among companies with meaningful P/E(ttm) only.
HZNP' s P/E(ttm) Range Over the Past 10 Years
Min: 81.83  Med: 170.28 Max: 217.27
Current: 212.24
81.83
217.27
Forward P/E 8.39
HZNP's Forward P/E is ranked higher than
85% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. HZNP: 8.39 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 212.24
HZNP's PE(NRI) is ranked lower than
94% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.39 vs. HZNP: 212.24 )
Ranked among companies with meaningful PE(NRI) only.
HZNP' s PE(NRI) Range Over the Past 10 Years
Min: 81.05  Med: 166.50 Max: 212.44
Current: 212.24
81.05
212.44
Price/Owner Earnings (ttm) 31.94
HZNP's Price/Owner Earnings (ttm) is ranked higher than
55% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. HZNP: 31.94 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HZNP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 0.01  Med: 27.69 Max: 31.97
Current: 31.94
0.01
31.97
P/B 2.40
HZNP's P/B is ranked higher than
58% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. HZNP: 2.40 )
Ranked among companies with meaningful P/B only.
HZNP' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 2.31 Max: 14.94
Current: 2.4
0.8
14.94
P/S 3.60
HZNP's P/S is ranked lower than
58% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. HZNP: 3.60 )
Ranked among companies with meaningful P/S only.
HZNP' s P/S Range Over the Past 10 Years
Min: 1.34  Med: 4.15 Max: 12.65
Current: 3.6
1.34
12.65
PFCF 10.00
HZNP's PFCF is ranked higher than
84% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. HZNP: 10.00 )
Ranked among companies with meaningful PFCF only.
HZNP' s PFCF Range Over the Past 10 Years
Min: 7.01  Med: 41.29 Max: 499.62
Current: 10
7.01
499.62
POCF 9.60
HZNP's POCF is ranked higher than
78% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. HZNP: 9.60 )
Ranked among companies with meaningful POCF only.
HZNP' s POCF Range Over the Past 10 Years
Min: 6.73  Med: 36.16 Max: 223.97
Current: 9.6
6.73
223.97
EV-to-EBIT 163.13
HZNP's EV-to-EBIT is ranked lower than
96% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. HZNP: 163.13 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.60 Max: 219.8
Current: 163.13
-775.4
219.8
EV-to-EBITDA 19.68
HZNP's EV-to-EBITDA is ranked lower than
57% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. HZNP: 19.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.40 Max: 518
Current: 19.68
-608
518
Current Ratio 1.98
HZNP's Current Ratio is ranked lower than
60% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. HZNP: 1.98 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.99 Max: 4.39
Current: 1.98
0.16
4.39
Quick Ratio 1.57
HZNP's Quick Ratio is ranked lower than
57% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. HZNP: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.80 Max: 4.27
Current: 1.57
0.16
4.27
Days Inventory 69.20
HZNP's Days Inventory is ranked higher than
76% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. HZNP: 69.20 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 48.48 Max: 184.95
Current: 69.2
13.1
184.95
Days Sales Outstanding 124.86
HZNP's Days Sales Outstanding is ranked lower than
80% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. HZNP: 124.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.38  Med: 89.59 Max: 124.99
Current: 124.86
64.38
124.99
Days Payable 94.93
HZNP's Days Payable is ranked higher than
67% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. HZNP: 94.93 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 193.90 Max: 410.36
Current: 94.93
27.59
410.36

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.65
HZNP's Price/Projected FCF is ranked lower than
51% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. HZNP: 2.65 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.3  Med: 6.48 Max: 29.51
Current: 2.65
2.3
29.51
Price/Median PS Value 0.87
HZNP's Price/Median PS Value is ranked higher than
75% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. HZNP: 0.87 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.04 Max: 2.72
Current: 0.87
0.38
2.72
Earnings Yield (Greenblatt) (%) 0.61
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. HZNP: 0.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.70 Max: 1.9
Current: 0.61
0.5
1.9

More Statistics

Revenue (TTM) (Mil) $848.6
EPS (TTM) $ 0.09
Beta1.47
Short Percentage of Float15.28%
52-Week Range $12.86 - 38.46
Shares Outstanding (Mil)160.36

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,006 1,166 1,304
EPS ($) 2.23 3.64 3.25
EPS w/o NRI ($) 2.23 3.64 3.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:HZNP

Headlines

Articles On GuruFocus.com
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
Nuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in... Jul 13 2016
Check out Horizon’s Huge Upside Potential Jul 12 2016
Horizon Pharma (HZNP) Stock Rises, Morgan Stanley Upgrades Jul 11 2016
Morning Movers: Alexion Pharma Gains on Upgrade; Alcoa Rises Ahead of Earnings Jul 11 2016
Horizon Pharma upgraded by Morgan Stanley Jul 11 2016
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016 Jul 07 2016
Inside Horizon’s Orphan and Rheumatology Business Unit Jul 07 2016
What’s Really Driving Horizon’s Valuation? Jul 07 2016
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016 Jul 07 2016
The Truth behind Horizon’s EV-to-EBITDA Performance Jun 30 2016
How Is Horizon Pharma Looking on a Price-to-Sales Basis? Jun 30 2016
Horizon (HZNP) Stock Up on Ravicti Label Expansion Filing Jun 30 2016
Horizon Pharma (HZNP) Stock Closed Up as BMO Initiates Coverage Jun 29 2016
Clinigen Group - New MA program with Horizon Pharma Jun 29 2016
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol... Jun 29 2016
Clinigen and Horizon Pharma enter partnership to initiate European Managed Access program for... Jun 29 2016
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol... Jun 29 2016
Here’s Why Traders Are Watching These Stocks Today Jun 28 2016
Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : June 28, 2016 Jun 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)